SCHEMBL3252153

SCHEMBL3252153

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)N(CCC#N)C4CC4)cc3c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
GLA P06280 1/20 0.39
MAPT P10636 5/20 0.38
LMNA P02545 3/20 0.38
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
TP53 P04637 1/20 0.36
GABRA1 P14867 2/20 0.35
GABRB2 P47870 2/20 0.35
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRA3 P34903 1/20 0.34
HSD17B10 Q99714 3/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
CYP2C9 P11712 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248550 0.89 KDM4E (0.41) KDM4EALDH1A1HPGDGLAMAPT
SCHEMBL3253881 0.88 ALDH1A1 (0.37) KDM4EALDH1A1HPGDGLAMAPT
SCHEMBL3251345 0.84 KDM4E (0.38) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL13950882 0.83 KDM4E (0.38) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL13928164 0.82 MAPT (0.39) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL3249780 0.82 KDM4E (0.49) KDM4EALDH1A1HPGDGLAMAPT
SCHEMBL3249025 0.81 MAPT (0.52) KDM4EALDH1A1HPGDMAPTLMNA
Hydrochloric Acid SCHEMBL3254799 0.81 MAPT (0.38) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL4159469 0.81 KDM4E (0.37) KDM4EALDH1A1HPGDGLAMAPT
SCHEMBL13950821 0.81 MAPT (0.34) KDM4EALDH1A1HPGDMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 KDM4E 1970/4885ALDH1A1 3830/4885HPGD 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.